Liste des publications
La recherche de l'équipe ODPM, pendant plus que 20 ans, a été publié dans les journaux majeurs permettant une validation et recognition par la communauté médicale internationale.
Capitain O, Seegers V, Metges JP et al. Journal of Clinical Oncology 37, no. 15 suppl, 3529 (2019)
Boisdron-Celle M, Capitain O, Faroux R et al. Seminars in Oncology Vol 44 (1), 12 - 23 (2017)
Boisdron-Celle M, Metges JP, Capitain O et al. Seminars in Oncology Vol 44 (1), 24 - 33 (2017)
Boisdron-Celle M, Gamelin E, Morel A.  EMC Biologie médicale  Article 90-45-0075-A (2017)
Boisdron-Celle M, Capitain O, Metges JP et al.  WCGC GI Barcelone 2014 Poster PD 007.

Gamelin E, Boisdron-Celle M, Morel A. Oncologie (Springer Verlag-France) 16, 96-102 (2014).


31 - Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracile.

Boisdron-Celle M, Biason P, Gamelin E et al. Colorectal Cancer 2(6), 1-11 (2013).


30 - 5-fluorouracile: MSI, phamacocinétique, DPD, TYMS et MTHFR. Chapitre 6 du livre «Médecine Personnalisée en Cancérologie Digestive, vers un traitement à la carte» édition 2013 Springer 

Boisdron-Celle M, Guérin-Meyer V, Capitain O.


29 - Actualités en Pharmacovigilance: 5-Fluorouracile et capécitabine: éviter les toxicités potentiellement mortelles."Le dépistage prèthérapeutique du déficit en DPD doit devenir une nécessité..."

Edition n°50 d'avril 2013 du Bulletin d'information du Centre Régional de Pharmacovigilance d'Angers


28 - Prevention of 5-FU-induced health-threatening toxicity by pre-therapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Farou R at al. Asco Annual Meeting 2013 Abstract 3601


27 - Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared with Conventional BSA Dosing: A Phase 2, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M et al. Clin Col Cancer. 11(4), 263-267 (2012).


26 - Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going?

Boisdron-Celle M. Pharmacogenomics. Editorial. 13(13), 1437-1439 (2012).


25 - Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols

Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.

Boisdron-Celle M, Le Guellec C. Therapie. 65(3), 171-176 (2010).


24 - Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation
Mounier-Boutoille H, Boisdron-Celle M, Cauchin E et al. Br J Clin Pharmacol. 70(2), 280-283 (2010).


23 - Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine. 
Boisdron-Celle M, Morel A, Gamelin E
Ann Biol Clin. 68(1), 27-32 (2010).


22 - Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer
Beumer JH, Boisdron-Celle M, Clarke W et al. 
Ther Drug Monit. 31(6), 688-694 (2009).


21 - Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Rouits E, Charasson V, Pétain A et al. Br J Cancer. 99(8), 1239-1245 (2008).


20 - Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E, Delva R, Jacob J et al. J Clin Oncol. 26(13), 2099-2105 (2008).


19 - The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
Capitain O, Boisdron-Celle M, Poirier AL et al. Pharmacogenomics J. 8(4), 256-267 (2008).


18 - A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.
Blasco H, Boisdron-Celle M, Bougnoux P et al.
 Br J Clin Pharmacol. 65(6), 966-970 (2008).


17 - Pharmacogenetics of anti-cancer drugs.

Gamelin E, Boisdron-Celle M, Morel A et al. Ann Pharm Fr. 65(6), 390-401 (2007). 


16 - Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Beneton M, Chapet S, Blasco H et al.
Br J Clin Pharmacol. 64(5), 613-621 (2007).


15 - Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines.
Gamelin E, Boisdron-Celle M, Morel A.
Therapie. 62(2), 99-103 (2007).


14 - 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

Boisdron-Celle M, Remaud G, Traore S et al. Cancer Lett. 249(2), 271-282 (2007). 

13 - Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma
Morel A, Boisdron-Celle M, Fey L et al.
 Clin Biochem. 40(1-2), 11-17 (2007).


12 - Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

Morel A, Boisdron-Celle M, Fey L et al. Mol Cancer Ther. 5(11), 2895-2904 (2006).

11 - An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.
Remaud G, Boisdron-Celle M, Hameline C et al
J Chromatogr B Analyt Technol Biomed Life Sci. 823(2), 98-107 (2005).

10 - Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences
Boisdron-Celle M, Craipeau C, Brienza S et al. 
Cancer Chemother Pharmacol. 49(3), 235-243 (2002). 

9 - Pharmacokinetic monitoring.
Boisdron-Celle M, Boulanger N, Gamelin E
Bull Cancer. 87(1), 86-92 (2000). 

8 - Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E, Boisdron-Celle M, Guérin-Meyer V et al. J Clin Oncol. 17(4), 1105-1110 (1999).

7 - Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Gamelin E, Boisdron-Celle M.
Crit Rev Oncol Hematol. 30(1), 71-79 (1999). 

6 - Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
Gamelin E, Boisdron-Celle M, Delva R et al.
 J Clin Oncol. 16(4), 1470-1478 (1998).


5 - A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites.

Gamelin E, Boisdron-Celle M, Larra F, Robert J. J Liqu Chrom Rel Tech 20(19), 3155-3172 (1997).


4 - Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma.
Gamelin E, Boisdron-Celle M, Turcant A et alJ Chromatogr B Biomed Sci Appl. 695(2), 409-416 (1997).

3 - Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E, Bouil AL, Boisdron-Celle M et al. Clin Cancer Res. 3(6), 891-899 (1997).

2 - Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.
Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. 
Cancer. 77(3), 441-451 (1996).

1 - Individual dose adjustment in anticancer chemotherapy.

Gamelin E, Boisdron-Celle M. Rev Med Interne. 17(7), 529-533 (1996).